Drug intelligence / Profile preview

adenosine

Development stage
Approved
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Intravenous, Ophthalmic, Intramuscular
01

Overview

Adenosine is an endogenous purine nucleoside and a fundamental building block of RNA. Pharmacologically, it acts as an agonist at four G-protein-coupled adenosine receptors (A1, A2A, A2B, and A3), modulating numerous physiological processes including cardiac conduction, vasodilation, neurotransmission, and immune response. Clinically, intravenous adenosine is used for the acute conversion of paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm and as a diagnostic agent in myocardial perfusion imaging for patients unable to exercise adequately. Its antiarrhythmic effect is mediated by slowing conduction through the atrioventricular node via hyperpolarization of cardiac cells. Adenosine has a very short half-life (<10 seconds) due to rapid cellular uptake and metabolism[1][7][8]. It also plays roles in neuroprotection during hypoxia or ischemia and has been investigated for its effects on sleep regulation, pain modulation, inflammation control, and potential involvement in neurodegenerative diseases[2][5][9].

Brand names
AdenocardAdenoscan
Other names
adenine riboside腺苷
02

Targets

ADORA3 (Adenosine A3 receptor)ADORA2B (Adenosine A2B receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on adenosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on adenosine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call